Equity Profile

BSX

Boston Scientific Corporation

Health CareHealth Care Equipment$72.2B

Feb10Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EST

Company Snapshot

Boston Scientific Corporation (BSX) is a leading global medical device manufacturer that develops innovative technologies to improve patient outcomes. Operating in the health care sector, the company focuses on areas such as cardiovascular, rhythm management, and endoscopy, which are critical as the demand for advanced medical solutions continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.80

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and drive sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BSX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

In Q1-2026, Boston Scientific reported an EPS of $0.80, matching analyst expectations and resulting in a positive stock reaction of nearly 9% the following day. The company has consistently beaten EPS estimates over the past quarters, indicating strong operational performance.

Management Promises & Guidance

Continue to focus on innovation in medical devices.
Expand market presence in key therapeutic areas.
Enhance operational efficiency to improve margins.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Boston Scientific's upcoming earnings, given its strong track record of beating EPS estimates. However, there is uncertainty regarding revenue growth and the impact of new product launches.

Bull Case

If the company reports strong EPS and demonstrates robust revenue growth driven by new product launches, it could lead to a significant positive reaction in the stock price.

Bear Case

Conversely, if revenue growth falls short of expectations or if there are concerns about market competition, the stock could face downward pressure.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.80

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market share and drive sales, which is crucial for long-term success.

Product Launch Impact

N/A

New product launches can significantly affect sales and market perception, making it important to assess their performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth for the quarter?

Revenue growth is crucial for assessing the company's ability to expand and compete effectively in the medical device market.

How have recent product launches impacted sales?

Understanding the performance of new products will provide insights into the company's innovation strategy and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Boston Scientific has a strong track record of beating EPS estimates, suggesting potential for upside.

Options pricing indicates lower expected volatility, which may not reflect the company's growth potential.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the balance between maintaining profitability and achieving strong revenue growth amid competitive pressures.

Bull Confirmed If

Revenue growth exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

Any revenue growth below 5% could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.36%

Historical Avg

±5.3%

Pricing cheap

The options market is pricing in a modest move of about 1.36%, suggesting that investors expect relatively stable performance around the earnings report.

Options are pricing ±1.4% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

59.7%

Calls (28.2M)P/C Ratio: 0.21Puts (7.0M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats EPS expectations and raises guidance, history suggests a potential stock increase of around 0.45% on the following day.

In-Line / Cautious

If results come in line with expectations but management provides cautious commentary, the stock may experience muted movement.

Miss

Should the company miss earnings expectations, history suggests a possible decline of around 0.45% or more in the stock price.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·2 sells

Members

House + Senate

Est. Notional

$19,005.00–$110,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the impact of new product launches on sales.
2Management's outlook on revenue growth for the upcoming quarters.
3Insights into competitive pressures in the medical device market.
4Details on operational efficiencies and margin improvements.
5Any commentary on market trends affecting the health care equipment sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb8

HMYReported

Harmony Gold Mining Company Limited

RecapView

Feb8

CNAReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.80

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and drive sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BSX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

Management Promises & Guidance

Continue to focus on innovation in medical devices.
Expand market presence in key therapeutic areas.
Enhance operational efficiency to improve margins.

Expectations

Wall Street Expectations

Bull Case

If the company reports strong EPS and demonstrates robust revenue growth driven by new product launches, it could lead to a significant positive reaction in the stock price.

Bear Case

Conversely, if revenue growth falls short of expectations or if there are concerns about market competition, the stock could face downward pressure.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.80

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market share and drive sales, which is crucial for long-term success.

Product Launch Impact

N/A

New product launches can significantly affect sales and market perception, making it important to assess their performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth for the quarter?

Revenue growth is crucial for assessing the company's ability to expand and compete effectively in the medical device market.

How have recent product launches impacted sales?

Understanding the performance of new products will provide insights into the company's innovation strategy and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Boston Scientific has a strong track record of beating EPS estimates, suggesting potential for upside.

Options pricing indicates lower expected volatility, which may not reflect the company's growth potential.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the balance between maintaining profitability and achieving strong revenue growth amid competitive pressures.

Bull Confirmed If

Revenue growth exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

Any revenue growth below 5% could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.36%

Historical Avg

±5.3%

Pricing cheap

The options market is pricing in a modest move of about 1.36%, suggesting that investors expect relatively stable performance around the earnings report.

Options are pricing ±1.4% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

59.7%

Calls (28.2M)P/C Ratio: 0.21Puts (7.0M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats EPS expectations and raises guidance, history suggests a potential stock increase of around 0.45% on the following day.

In-Line / Cautious

If results come in line with expectations but management provides cautious commentary, the stock may experience muted movement.

Miss

Should the company miss earnings expectations, history suggests a possible decline of around 0.45% or more in the stock price.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·2 sells

Members

House + Senate

Est. Notional

$19,005.00–$110,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the impact of new product launches on sales.
2Management's outlook on revenue growth for the upcoming quarters.
3Insights into competitive pressures in the medical device market.
4Details on operational efficiencies and margin improvements.
5Any commentary on market trends affecting the health care equipment sector.